Jane C.K. Fitch

Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes

Bruce D. Spiess, David Royston, Jerrold H. Levy et al. · Transfusion · 2004 · 315 citations

Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass

Jane C.K. Fitch, Scott A. Rollins, Louis A. Matis et al. · Circulation · 1999 · 284 citations · Full text

Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Christine S. Rinder, Henry M. Rinder, Brian R. Smith et al. · Journal of Clinical Investigation · 1995 · 213 citations · Full text

Inflammation, Thrombosis, Complement System +14

Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass

Stanton K. Shernan, Jane C.K. Fitch, Nancy A. Nussmeier et al. · The Annals of Thoracic Surgery · 2004 · 110 citations · Full text

Cardiovascular Disease, Total Mortality, Cardiac Surgical Patients +6

Individual Variations in the Fibrinolytic Response During and After Cardiopulmonary Bypass

Wayne L. Chandler, Jane C.K. Fitch, M. Wall et al. · Thrombosis and Haemostasis · 1995 · 96 citations